GeneDx (NASDAQ:WGS - Get Free Report) released its quarterly earnings data on Tuesday. The company reported $0.50 EPS for the quarter, topping analysts' consensus estimates of $0.10 by $0.40, Zacks reports. GeneDx had a net margin of 0.39% and a return on equity of 16.51%. The firm had revenue of $102.69 million during the quarter, compared to analysts' expectations of $86.00 million. GeneDx updated its FY 2025 guidance to EPS.
GeneDx Price Performance
WGS traded down $0.35 on Friday, hitting $101.60. 835,293 shares of the stock were exchanged, compared to its average volume of 1,093,534. GeneDx has a 12 month low of $25.32 and a 12 month high of $117.75. The business has a 50-day moving average of $79.42 and a two-hundred day moving average of $82.76. The company has a debt-to-equity ratio of 0.19, a current ratio of 2.87 and a quick ratio of 3.07. The firm has a market capitalization of $2.90 billion, a price-to-earnings ratio of 2,032.00 and a beta of 2.01.
Analyst Ratings Changes
A number of equities research analysts have recently issued reports on WGS shares. Guggenheim reissued a "buy" rating and issued a $115.00 target price (up previously from $88.00) on shares of GeneDx in a research report on Monday, June 30th. Jefferies Financial Group raised shares of GeneDx from a "hold" rating to a "buy" rating and set a $80.00 target price for the company in a research report on Friday, May 9th. Wells Fargo & Company boosted their target price on shares of GeneDx from $78.00 to $95.00 and gave the company an "equal weight" rating in a research report on Wednesday. Piper Sandler started coverage on shares of GeneDx in a research report on Wednesday, July 9th. They issued an "overweight" rating and a $110.00 target price for the company. Finally, TD Securities reduced their target price on shares of GeneDx from $135.00 to $110.00 and set a "buy" rating for the company in a research report on Thursday, May 1st. Three equities research analysts have rated the stock with a hold rating and six have issued a buy rating to the company. According to data from MarketBeat, the company has an average rating of "Moderate Buy" and an average target price of $100.38.
View Our Latest Report on GeneDx
Insider Buying and Selling
In other GeneDx news, Director Keith A. Meister bought 100,000 shares of the stock in a transaction on Thursday, May 8th. The stock was purchased at an average price of $56.01 per share, with a total value of $5,601,000.00. Following the completion of the purchase, the director owned 3,008,629 shares in the company, valued at $168,513,310.29. The trade was a 3.44% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available through the SEC website. Also, CEO Katherine Stueland sold 2,154 shares of the business's stock in a transaction dated Tuesday, July 29th. The stock was sold at an average price of $105.31, for a total value of $226,837.74. Following the transaction, the chief executive officer directly owned 3,440 shares of the company's stock, valued at approximately $362,266.40. The trade was a 38.51% decrease in their position. The disclosure for this sale can be found here. Insiders sold 22,411 shares of company stock valued at $2,085,051 over the last quarter. 29.60% of the stock is owned by company insiders.
Institutional Inflows and Outflows
Several institutional investors and hedge funds have recently made changes to their positions in the company. NewEdge Advisors LLC boosted its holdings in GeneDx by 270,700.0% in the first quarter. NewEdge Advisors LLC now owns 2,708 shares of the company's stock valued at $240,000 after acquiring an additional 2,707 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its holdings in shares of GeneDx by 6.3% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 7,641 shares of the company's stock worth $677,000 after buying an additional 453 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its holdings in shares of GeneDx by 67.5% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 28,224 shares of the company's stock worth $2,500,000 after buying an additional 11,375 shares in the last quarter. Finally, Royal Bank of Canada boosted its holdings in shares of GeneDx by 30.2% during the 1st quarter. Royal Bank of Canada now owns 29,479 shares of the company's stock worth $2,611,000 after buying an additional 6,840 shares in the last quarter. Institutional investors and hedge funds own 61.72% of the company's stock.
About GeneDx
(
Get Free Report)
GeneDx Holdings Corp., through its subsidiaries, provides genomics-related diagnostic and information services. The company offers Centrellis, an AI-driven health intelligence platform that integrates digital tools and artificial intelligence allowing scientists to ingest and synthesize clinical and genomic data to deliver comprehensive health insights.
Further Reading
Before you consider GeneDx, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and GeneDx wasn't on the list.
While GeneDx currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
